07:00 , Aug 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Endocrine disease Pyroglutamylated RFamide peptide receptor (QRFPR; GPR103) Mouse and in vitro studies suggest a GPR103 agonist could increase food intake to help treat...